<DOC>
	<DOCNO>NCT00732186</DOCNO>
	<brief_summary>The purpose study assess safety ipilimumab dasatinib combination therapy patient CML</brief_summary>
	<brief_title>Study Ipilimumab Dasatinib Combination Therapy Patients With Chronic Accelerated Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Ph+ CML dasatinib therapy Loss cytogenetic molecular response dasatinib therapy On stable dose dasatinib minimum 12 week &lt; 14 day interruption treatment Blast crisis CML Autoimmune disease Uncontrolled significant cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>